(Total Views: 816)
Posted On: 02/14/2022 3:33:21 AM
Post# of 154118
What cancers will leronlimab help? More than one would think.
Leronlimab increases NKT cells. It would seem that in NKT/T-cell based leukemia and lymphoma that leronlimab might be counter-indicated. But the development of NKT/T-cell leukemia and lymphoma is based on the overexpression of factors that aid tumor growth and downregulate tumor expressing genes. Those cancers have an association with the Epstein Barr virus and it's reactivation. Let us hope the recent spate of reactivations seen in longhaulers is not a precursor to an increase in NKT/T-cell leukemia and lymphoma.
A large factor in the progression of NKT/T-cell leukemia and lymphoma is PD-L1 overexpression on NK and T-cells through the MapK/NF-kb pathway. Overexpression of JAK/STAT is also implicated. All of which are downregulated by leronlimab.
Tumor suppressing genes that are downregulated in NKT/T-cell leukemia and lymphoma include p53 which is upregulated by leronlimab. In other tumor suppressing genes leronlimab acts on the same pathways that the tumor suppressing genes have.
Leronlimab increases NKT cells. It would seem that in NKT/T-cell based leukemia and lymphoma that leronlimab might be counter-indicated. But the development of NKT/T-cell leukemia and lymphoma is based on the overexpression of factors that aid tumor growth and downregulate tumor expressing genes. Those cancers have an association with the Epstein Barr virus and it's reactivation. Let us hope the recent spate of reactivations seen in longhaulers is not a precursor to an increase in NKT/T-cell leukemia and lymphoma.
A large factor in the progression of NKT/T-cell leukemia and lymphoma is PD-L1 overexpression on NK and T-cells through the MapK/NF-kb pathway. Overexpression of JAK/STAT is also implicated. All of which are downregulated by leronlimab.
Tumor suppressing genes that are downregulated in NKT/T-cell leukemia and lymphoma include p53 which is upregulated by leronlimab. In other tumor suppressing genes leronlimab acts on the same pathways that the tumor suppressing genes have.
(16)
(0)
